CK Wang, MD, chief medical officer of COTA, discusses how real-world data help identify disparities and gaps in cancer care.

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy ...

Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional ...

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says ...

As Obergefell v Hodges turns 10 years, LGBTQ+ rights face renewed threats amid political shifts, impacting health care equity ...

Panelists discuss how communication between clinicians, patients, and payers could improve equitable access to spinal ...

Panelists discuss how spinal muscular atrophy (SMA) treatment will evolve over the next 5 years, likely incorporating ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those receiving placebo.

South Carolina had previously barred abortion clinics, including Planned Parenthood, from participating in Medicaid, leaving many patients vulnerable to uncovered treatment.

John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease ...